JOURNAL ARTICLE

NIAAA/NIDA animal study: Diet drug may help treat AUD.

  • Published In: Alcoholism & Drug Abuse Weekly, 2024, v. 36, n. 12. P. 7 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Knopf, Alison 3 of 3

Abstract

Researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA), and collaborators from The Scripps Research Institute, have found that semaglutide (brand name for the injection drug is Wegovy) — a gut hormone that promotes a feeling of fullness and thus promotes weight loss — can help reduce alcohol consumption and binge‐like drinking. The research is based on a rodent model. Published in the June 2023 issue of the journal JCI Insight, the study adds to growing preclinical evidence that the glucagon‐like peptide‐1 (GLP‐1) system plays a role in alcohol and other substance use disorders, and that GLP‐1 receptor agonists show potential for treating people with alcohol use disorder (AUD). [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Alcoholism & Drug Abuse Weekly. 2024/03, Vol. 36, Issue 12, p7
  • Document Type:Article
  • Subject Area:Consumer Health
  • Publication Date:2024
  • ISSN:1042-1394
  • DOI:10.1002/adaw.34068
  • Accession Number:176078967
  • Copyright Statement:Copyright of Alcoholism & Drug Abuse Weekly is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.